Parenteral Cidofovir for Cytomegalovirus Retinitis in Patients with AIDS: The HPMPC Peripheral Cytomegalovirus Retinitis Trial: A Randomized, Controlled Trial
Journal: Annals of Internal Medicine (1997)

Articles15 February 1997Parenteral Cidofovir for Cytomegalovirus Retinitis in Patients with AIDS: The HPMPC Peripheral Cytomegalovirus Retinitis Trial: A Randomized, Controlled TrialAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-126-4-199702150-00002 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail AbstractBackground:Cytomegalovirus (CMV) retinitis is a common infection and a major cause of visual loss in patients with the acquired immunodeficiency syndrome (AIDS).Objective:To evaluate intravenous cidofovir as a treatment for CMV retinitis.Design:Two-stage, multicenter, phase II/III, randomized, controlled clinical trial.Setting:Ophthalmology and AIDS services at tertiary care medical centers.Patients:64 patients with AIDS and previously untreated, small, peripheral CMV retinitis lesions (that is, patients at low risk for loss of visual acuity).Intervention:Patients were randomly assigned to one of three groups: the deferral group, in which treatment was deferred until retinitis progressed; the low-dose cidofovir group, which received cidofovir, 5 mg/kg of body weight once weekly for 2 weeks, then maintenance therapy with cidofovir, 3 mg/kg once every 2 weeks; or the high-dose cidofovir group, which received cidofovir, 5 mg/kg once weekly for 2 weeks, then maintenance therapy with cidofovir, 5 mg/kg once every 2 weeks. To minimize nephrotoxicity, cidofovir was administered with hydration and probenecid.Measurements:Progression of retinitis, evaluated in a masked manner by a fundus photograph reading center; the amount of retinal area involved by CMV; the loss of visual acuity; and morbidity.Results:Median time to progression was 64 days in the low-dose cidofovir group and 21 days in the deferral group (P = 0.052, log-rank test). The median time to progression was not reached in the high-dose cidofovir group but was 20 days in the deferral group (P = 0.009, log-rank test). Analysis of the rates of increase in the retinal area affected by CMV confirmed the data on time to progression. The three groups had similar rates of visual loss. Proteinuria of 2+ or more occurred at rates of 2.6 per person-year in the deferral group, 2.8 per person-year in the low-dose cidofovir group (P > 0.2), and 6.8 per person-year in the high-dose cidofovir group (P = 0.135). No patient developed 4+ proteinuria, but two cidofovir recipients developed persistent elevations of serum creatinine levels at more than 177 µmol/L (2.0 mg/dL). Reactions to probenecid occurred at a rate of 0.70 per person-year.Conclusions:Intravenous cidofovir, high- or low-dose, effectively slowed the progression of CMV retinitis. Concomitant probenecid and hydration therapy, intermittent dosing, and monitoring for proteinuria seemed to minimize but not eliminate the risk for nephrotoxicity.References1. Moore RD, Chaisson RE. Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann Intern Med. 1996; 124:633-42. Google Scholar2. Hoover DR, Saah AJ, Bacellar H, Phair J, Detels R, Anderson R, et al. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study. N Engl J Med. 1993; 329:1922-6. Google Scholar3. Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. J Infect Dis. 1992; 166:1223-7. Google Scholar4. Jabs DA, Enger C, Bartlett JG. Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Arch Ophthalmol. 1989; 107:75-80. Google Scholar5. Jabs DA. Ocular manifestations of HIV infection. Trans Am Ophthalmol Soc. 1995; 93:623-83. Google Scholar6. Pertel P, Hirschtick R, Phair J, Chmiel J, Poggensee L, Murphy R. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus. J Acquir Immune Defic Syndr. 1992; 5:1069-74. Google Scholar7. Kuppermann BD, Petty JG, Richman DD, Mathews WC, Fullerton SC, Rickman LS, et al. Correlation between CD4+ counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome. Am J Ophthalmol. 1993; 115:575-82. Google Scholar8. Spector SA, Weingeist T, Pollard RB, Dieterich DT, Samo T, Benson CA, et al. A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. AIDS Clinical Trials Group and Cytomegalovirus Cooperative Study Group. J Infect Dis. 1993; 168:557-63. Google Scholar9. Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med. 1992; 326:213-20. Google Scholar10. Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial. 4. Visual outcomes. Ophthalmology. 1994; 101:1250-61. Google Scholar11. Intravenous versus oral ganciclovir: European/Australian comparative study of efficacy and safety in the prevention of cytomegalovirus retinitis recurrence in patients with AIDS. The Oral Ganciclovir European and Australian Cooperative Study Group. AIDS. 1995; 9:471-7. Google Scholar12. Drew WL, Ives D, Lalezari JP, Crumpacker C, Follansbee SE, Spector SA, et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study Group. N Engl J Med. 1995; 333:615-20. Google Scholar13. Palestine AG, Polis MA, De Smet MD, Baird BF, Falloon J, Kovacs JA, et al. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann Intern Med. 1991; 115:665-73. Google Scholar14. Martin DF, Parks DJ, Mellow SD, Ferris FL, Walton RC, Remaley NA, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized, controlled clinical trial. Arch Ophthalmol. 1994; 112:1531-9. Google Scholar15. Bronson JJ, Ghazzouli I, Hitchcock MJ, Webb RR 2d, Martin JC. Synthesis and antiviral activity of the nucleotide analogue (S)-1-[3-hydroxy-2-(phosphonylmethoxy) propyl]cytosine. J Med Chem. 1989; 32:1457-63. Google Scholar16. Hitchcock MJ, Woods K, Bronson J, Martin JC, Ho HT. Intracellular metabolism of the anti-herpes agent, (S)-1-[3-hydroxy-2-(phosphonylmethoxy) propyl]cytosine (HPMPC). Mol Pharmacol. 1992; 41:197-202. Google Scholar17. Snoeck R, Sakuma T, De Clercq E, Rosenberg I, Holy A. (S)-1-[3-hydroxy-2-(phosphonylmethoxy) propyl]cytosine, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob Agents Chemother. 1988; 32:1839-44. Google Scholar18. De Castro LM, Kern ER, De Clercq E, Ghaffar A, Mayer EP, Vogt PE, et al. Phosphonylmethoxyalkyl purine and pyrimidine derivatives for treatment of opportunistic cytomegalovirus and herpes simplex virus infections in murine AIDS. Antiviral Res. 1991; 16:101-14. Google Scholar19. Soike K, Huang JL, Zhang JY, Bohm R, Hitchcock MJ, Martin JC. Evaluation of infrequent dosing regimens with (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (HPMPC) on Simian Varicella infection in monkeys. Antiviral Res. 1991; 16:17-28. Google Scholar20. Li SB, Yang ZH, Feng JS, Fong CK, Lucia HL, Hsiung GD. Activity of (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (HPMPC) against guinea pig cytomegalovirus infection in cultured cells and in guinea pigs. Antiviral Res. 1990; 13:237-52. Google Scholar21. Lalezari JP, Drew WL, Glutzer E, James C, Miner D, Flaherty J, et al. (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase l/II study of a novel antiviral nucleotide analogue. J Infect Dis. 1995; 171:788-96. Google Scholar22. Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Studies of ocular complications of AIDS Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 1. Rationale, design, and methods. Control Clin Trials. 1992; 13:22-39. Google Scholar23. Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH. The use of nitrogen mustards in the palliative treatment of carcinoma: with particular reference to bronchogenic carcinoma. Cancer. 1948; 1:634-56. Google Scholar24. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep. 1992; 41(RR-17):1-19. Google Scholar25. Petty BG, Kornhauser DM, Lietman PS. Zidovudine with probenecid: a warning [Letter]. Lancet. 1990; 335:1044-5. Google Scholar26. Ferris FL 3d, Kassoff A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol. 1982; 94:91-6. Google Scholar27. Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. Arch Ophthalmol. 1996; 114:23-33. Google Scholar28. Holland GN, Buhles WC Jr, Mastre B, Kaplan HJ. A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy. Use of a standardized system for the assessment of disease outcome. UCLA CMV Retinopathy. Study Group. Arch Ophthalmol. 1989; 107:1759-66. Google Scholar29. Altman DG. Practical Statistics for Medical Research. New York: Chapman & Hall; 1991. Google Scholar30. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Journal of the American Statistical Association. 1958; 53:457-81. Google Scholar31. Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics. 1982; 38:29-41. Google Scholar32. Lin DO, Wei LS. The robust inference for the Cox proportional-hazards model. Journal of the American Statistical Association. 1989; 84:1074-7. Google Scholar33. Breslow N. Test of hypotheses in an overdispersed Poisson regression and other quasi-likelihood models. Journal of the American Statistical Association. 1990; 85:565-71. Google Scholar34. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986; 73:13-22. Google Scholar35. Breslow N, Day NE. Statistical Methods in Cancer Research. Lyon, France: International Agency for Research on Cancer; 1989:93-4. Google Scholar36. Kirsch LS, Arevalo JF, De Clercq E, Chavez de la Paz E, Munguia D, Garcia R, et al. Phase I/ll study of intravitreal cidofovir for the treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol. 1995; 119:466-76. Google Scholar37. Rahhal FM, Arevalo JF, Chavez de la Paz E, Munguia D, Azen SP, Freeman WR. Treatment of cytomegalovirus retinitis with intravitreous cidofovir in patients with AIDS. A preliminary report. Ann Intern Med. 1996; 125:98-103. Google Scholar Author, Article, and Disclosure InformationGrant Support: In part by cooperative agreements from the National Eye Institute to the Johns Hopkins University School of Medicine (U10 EY 08052), the Johns Hopkins University School of Hygiene and Public Health (U10 EY 08057), and the University of Wisconsin School of Medicine (U10 EY 08067). Additional support was provided by the National Center for Research Resources through General Clinical Research Center grants 5M01 RR 00350 (Baylor College of Medicine), 5M01 RR 00035 and 5M01 RR 00722 (Johns Hopkins University), 5M01 RR 05096 (Louisiana State University at Tulane), 5M01 RR 00071 (Mount Sinai Medical Center), 5M01 RR 00048 (Northwestern University), 5M01 RR 000865 (University of California, Los Angeles), 5M01 RR 00083 (University of California, San Francisco), 5M01 RR 05280 (University of Miami), and 5M01 RR 00046 (University of North Carolina). Support was also provided by the National Institute of Allergy and Infectious Diseases through cooperative agreements U01 AI 27668 (Johns Hopkins University), U01 AI 27674 (Louisiana State University at Tulane), U01 AI 27667 (Mount Sinai Medical Center), U01 AI 27665 (New York University), U01 AI 25915 (Northwestern University), U01 AI 27660 (University of California, Los Angeles), U01 AI 27670 (University of California, San Diego), U01 AI 27663 (University of California, San Francisco), and U01 AI25868 (University of North Carolina). Drugs and additional support were provided by Gilead Sciences, Inc. (Foster City, California). Financial disclosure statements are on file at the Studies of Ocular Complications of AIDS Coordinating Center, Johns Hopkins University School of Hygiene and Public Health, 601 North Wolfe Street, Room 5010, Baltimore, MD 21287.Corresponding Author: Douglas A. Jabs, MD, Studies of Ocular Complications of AIDS Chairman's Office, the Wilmer Ophthalmological Institute, Johns Hopkins University School of Medicine, 550 North Broadway, Suite 700, Baltimore, MD 21205. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byAntiviral AgentsMapping Adverse Outcome Pathways for Kidney Injury as a Basis for the Development of Mechanism-Based Animal-Sparing Approaches to Assessment of NephrotoxicityClassification Criteria for Cytomegalovirus RetinitisBiologics for the Treatment of Recurrent Respiratory PapillomatosisEsophagitis in the Immunocompromised HostClinical and Imaging Factors Associated With the Outcomes of Tubercular Serpiginous-like ChoroiditisAcquired Immunodeficiency SyndromeRelationship Between Opacity of Cytomegalovirus Retinitis Lesion Borders and Severity of Immunodeficiency Among People With AIDSAntiviral Therapies for Herpesviruses: Current Agents and New DirectionsDrug Interactions of Non-HIV Antiviral AgentsInfective Uveitis, Retinitis, and ChorioretinitisAntiviral AgentsIncidence Rate and Risk Factors for Contralateral Eye Involvement among Patients with AIDS and Cytomegalovirus Retinitis Treated with Local TherapyClinical Management of Viral EncephalitisCytomegalovirusUveitis and Clinical TrialsAntivirals against Herpes VirusesOutcome of cytomegalovirus retinitis in immunocompromised patients without Human Immunodeficiency Virus treated with intravitreal ganciclovir injectionHIV-Associated InfectionsOcular complications of HIV/AIDS in the era of HAARTReferencesEsophagitis in the Immunocompromised HostThe Use of Antiviral Drugs During the Neonatal PeriodAntiviral TherapyUveitis, Retinitis, and ChorioretinitisAntiviral AgentsCytomegalovirus Retinitis and the Acquired Immunodeficiency Syndrome—Bench to Bedside: LXVII Edward Jackson Memorial LectureNon-HIV Antiviral AgentsAntiviral Drugs (Other than Antiretrovirals)Philosophy, Goals, and Approaches to Medical TherapyAcquired Immunodeficiency SyndromeANTIVIRAL AGENTSUveitis, Retinitis, and ChorioretinitisAntiviral AgentsOcular Inflammation in Anterior SegmentSystemic Viral Infections and the EyeIntraocular Properties of An Alkoxyalkyl Derivative of Cyclic 9-(S)-(3-Hydroxyl-2-Phosphonomehoxypropyl) Adenine, An Intravitreally Injectable Anti-HCMV Drug in Rabbit and Guinea PigAntiviral therapy of HSV-1 and -2Cytomegalovirus retinitisAnterior Segment and External Ocular Disorders Associated with Human Immunodeficiency Virus DiseaseAntiviral Therapy For HIV Patients With Renal InsufficiencyCidofovir for the Treatment of Adenoviral Infection in Pediatric Hematopoietic Stem Cell Transplant PatientsDisseminated adenovirus infection with respiratory failure in pediatric liver transplant recipients: Impact of intravenous cidofovir and inhaled nitric oxideCytomegalovirus Infections of the RetinaRetinal Disease in HIV-infected PatientsEnhanced antiproliferative effects of alkoxyalkyl esters of cidofovir in human cervical cancer cells in vitroHIV-ASSOCIATED RETINOPATHY IN THE HAART ERAGanciclovir implant in the treatment of cytomegalovirus retinitisAntiviral Therapies in Children: Has Their Time Arrived?Antiviral Drug-Induced NephrotoxicitySeven Years of HAART Impact on Ophthalmic Management of HIV-Infected PatientsDesign and development of oral drugs for the prophylaxis and treatment of smallpox infectionComparability of two fundus photograph reading centers in grading cytomegalovirus retinitis progressionPosterior segment manifestations of HIV/AIDSCOMPLICATIONS OF GANCICLOVIR IMPLANT SURGERY IN PATIENTS WITH CYTOMEGALOVIRUS RETINITISCare of the Adult Patient with HIV InfectionOphthalmologic Aspects of HIV InfectionClinical Potential of the Acyclic Nucleoside Phosphonates Cidofovir, Adefovir, and Tenofovir in Treatment of DNA Virus and Retrovirus InfectionsAntiviral PharmacotherapeuticsEsterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidneyDrug-Induced Renal Failure: Update on New Medications and Unique Mechanisms of NephrotoxicityPotential of acyclic nucleoside phosphonates in the treatment of DNA virus and retrovirus infectionsRapid Communication: Acute Renal Failure Associated with Tenofovir: Evidence of Drug-Induced NephrotoxicityAntiviral agents: Nonantiviral drugsGuidelines for Preventing Opportunistic Infections among HIV-Infected Persons—2002: Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America*Prepared by Henry Masur, MD, Jonathan E. Kaplan, MD, and King K. Holmes, MD, PhDA Safety Study of Oral Valganciclovir Maintenance Treatment of Cytomegalovirus RetinitisAIDS related opportunistic infections, going but not goneA Controlled Trial of Valganciclovir as Induction Therapy for Cytomegalovirus RetinitisFomivirsen for the treatment of cytomegalovirus retinitis11Internet Advance publication at ajo.com Feb 8, 2002.Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has reactivated or is persistently active despite other therapies in patients with AIDS11InternetAdvance publication at ajo.com Feb 8, 2002.Financial disclosures and conflict of interest statements are listed at the end of the article.Correspondence to Stephen L. Hutcherson, MBA, Cyclix Ltd. LLC, 11851 Rexmoor Drive, Richmond, VA 23236; fax: (804) 897-9544; e-mail: [email protected] requests to René Lanz, PhD, Novartis Ophthalmics AG, Grenzstrasse 10, CH-8180 Bülach, Switzerland; fax: (41) 1-862-0762; e-mail: [email protected]A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with aids11InternetAdvance publication at ajo.com Feb 8, 2002.Financial disclosures and conflict of interest statements are listed at the end of the article.Reprint requests to René Lanz, PhD, Novartis Ophthalmics AG, Grenzstrasse 10, CH-8180 Bülach, Switzerland; fax: (41) 1-862-0762; e-mail: [email protected] to Stephen L. Hutcherson, MBA, Cyclix Ltd. LLC, 11851 Rexmoor Drive, Richmond, VA 23236; fax: (804) 897-9544; e-mail: [email protected]Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS11InternetAdvance publication at ajo.com Feb 8, 2002.Financial disclosures and conflict of interest statements are listed at the end of the article.Correspondence to Stephen L. Hutcherson, MBA, Cyclix Ltd. LLC, 11851 Rexmoor Drive, Richmond, VA 23236; fax: (804) 897-9544; e-mail: [email protected] requests to René Lanz, PHD, Novartis Ophthalmics AG, Grenzstrasse 10, CH-8180 Bülach, Switzerland; fax: (41) 1-862-0762; e-mail: [email protected]Treating Cytomegalovirus Retinitis-Related Retinal Detachment By Combining Silicone Oil Tamponade and Ganciclovir ImplantHigh dose oral ganciclovir treatment for cytomegalovirus retinitisAntiviral therapy for cytomegalovirus infections in pediatric patientsCNS Manifestations of Cytomegalovirus Infections2001 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus July 2001: DRAFTOral valganciclovir: a new option for treatment of cytomegalovirus infection and disease in immunocompromised hostsAcyclovir derivatives and other new antiviral agentsOphthalmic manifestations of immunodeficiency statesThe ganciclovir implant plus oral ganciclovir versus parenteral cidofovir for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndromeEarly diagnosis of adenovirus infection and treatment with cidofovir after bone marrow transplantation in childrenPatient Notification and Follow-up after Suspension of Treatment ProtocolsUveitisProphylaxis against Herpesvirus Infections in Transplant RecipientsEconomic Evaluation of Systemic Treatments for Cytomegalovirus Retinitis in Patients with AIDSIncremental Cost Effectiveness of Prophylaxis for Cytomegalovirus Disease in Patients with AIDSManagement and Prevention of Opportunistic Infections in the HIV-Infected PatientSuccessful Treatment of Juvenile Laryngeal Papillomatosis-Related Multicystic Lung Disease With CidofovirA review of antiviral therapies in the treatment of cytomegalovirusLong-term follow-up of patients with AIDS treated with parenteral cidofovir for cytomegalovirus retinitis: the HPMPC Peripheral Cytomegalovirus Retinitis TrialProphylaxis against Opportunistic Infections in Patients with Human Immunodeficiency Virus InfectionHighly active antiretroviral therapy–related immune recovery in AIDS patients with cytomegalovirus retinitis11The authors do not have any proprietary interest in any product mentioned in the text.Recent advances in the therapy and prevention of CMV infectionsPlant-Derived and Semi-Synthetic Calanolide Compounds with in Vitro Activity against Both Human Immunodeficiency Virus Type 1 and Human CytomegalovirusTherapeutic developments in cytomegalovirus retinitis1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virusIntravenous Cidofovir for Compassionate Use in AIDS Patients with Cytomegalovirus Retinitis1999 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency VirusUSPHS/IDSA Prevention of Opportunistic Infections Working GroupAntiviral Agents for Non-Human Immunodeficiency Virus InfectionsCytomegalovirus Retinitis in Advanced HIV-Infected Patients Treated With Protease Inhibitors: Incidence and Outcome Over 2 YearsCytomegalovirus Retinitis in Advanced HIV-Infected Patients Treated With Protease Inhibitors: Incidence and Outcome Over 2 YearsCurrent antiviral strategies for controlling cytomegalovirus in hematopoietic stem cell transplant recipients: prevention and therapyQuantitative changes in cytomegalovirus DNAemia and genetic analysis of the UL97 and UL54 genes in AIDS patients receiving cidofovir following ganciclovir therapyIntravitreal Toxicology and Therapeutic Efficacy of the Carboxymethyl Ester of the l- O -Octadecyl- sn -Glycerol-3-Phosphonoformate (ODG-PFA-O-Me), a Novel Lipid Antiviral Prodrug for Intraocular Drug DeliveryAntiviral Therapy For HIV Patients With Renal InsufficiencyAntiviral Therapy For HIV Patients With Renal InsufficiencyManagement of Viral InfectionsA Recombinant Human Cytomegalovirus with a Large Deletion in UL97 Has a Severe Replication DeficiencyCytomegalovirus Retinitis in the Era of Highly Active Antiretroviral Therapy (HAART)Ocular complications of intravenous cidofovir for cytomegalovirus retinitis in patients with AIDSCytomegalovirus Retinitis in the Era of Highly Active Antiretroviral Therapy (HAART)Antiinfectives Update: Focus on Treatment and Prevention of Viral and Associated InfectionsOral Ganciclovir for Patients with Cytomegalovirus Retinitis Treated with a Ganciclovir ImplantManagement of CMV Disease in HIV InfectionDer HIV-positive PatientChanging patterns of HIV related ocular diseaseCidofovirManagement of CMV Infections In HIV-Infected PatientsManagement of Cytomegalovirus Infections in Blood and Marrow Transplant RecipientsPharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis*Catheter complications in AIDS patients treated for cytomegalovirus retinitisCidofovir in the Treatment of Cytomegaloviral DiseaseManagement of Cytomegalovirus-Related Rhegmatogenous Retinal DetachmentsVirus infections of the eyeCytomegalovirus retinitis and viral resistance: 3. Culture resultsNews and views: Ongoing trials of the National Eye Institute IIOutcomes of cytomegalovirus retinitis following the use of ganciclovir implantsDiscontinuation of maintenance therapy in patients with quiescent cytomegalovirus retinitis and elevated CD4+ countsProbenecid Hypersensitivity in AIDS: a Case ReportAnterior uveitis and hypotony after intravenous cidofovir for the treatment of cytomegalovirus retinitis11The authors have no proprietary interest in any of the products referred to in this article.Randomized, Controlled Study of the Safety and Efficacy of Intravenous Cidofovir for the Treatment of Relapsing Cytomegalovirus Retinitis in Patients With AIDSHOW TO TREAT THE CYTOMEGALOVIRUS TROLLEpidemiology of infectious complications in cancer patientsCytomegalovirus disease in AIDSDevelopment of a point mutation assay for the detection of human cytomegalovirus UL97 mutations associated with ganciclovir resistanceClinical uses of cidofovirNursing Considerations in the use of Cidofovir for CMV Retinitis in Patients with AIDS: Report of a Roundtable MeetingIn vitro antiviral drug sensitivity of the Kaposi's sarcoma-associated herpesvirusAIDS and Ophthalmology: A Period of TransitionTreatment of Cytomegalovirus Retinitis with a Sustained-Release Ganciclovir ImplantTreatment of Cytomegalovirus Retinitis in Patients with the Acquired Immunodeficiency SyndromeUveitis 15 February 1997Volume 126, Issue 4 Page: 264-274 Keywords AIDS Creatinine Cytomegalovirus infection Lesions Morbidity Proteinuria Retinitis Urine Viremia Visual acuity ePublished: 15 August 2000 Issue Published: 15 February 1997 Copyright & PermissionsCopyright © 1997 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...